---
layout: post
title: New Drug Approvals 2012 - Pt. XXXV - Elvitegravir/Cobicistat/Emtricitabine/Tenofovir
  disoproxil fumerate (STRIBILD®)
date: '2013-01-27T08:31:00.000Z'
author: Ramesh
tags:
- Small Molecule Drugs
- Combination Drugs
- 2012 New Drugs
modified_time: '2013-01-28T10:02:50.967Z'
thumbnail: http://1.bp.blogspot.com/-ho2HWbx3HEU/UQZMo80HgpI/AAAAAAAAAFo/x-ra7hYOBNc/s72-c/Screen+Shot+2013-01-28+at+10.01.23.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-2391511899782179956
blogger_orig_url: http://chembl.blogspot.com/2013/01/new-drug-approvals-2012-pt-xxxv_27.html
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: center;">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://1.bp.blogspot.com/-ho2HWbx3HEU/UQZMo80HgpI/AAAAAAAAAFo/x-ra7hYOBNc/s1600/Screen+Shot+2013-01-28+at+10.01.23.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="142" src="http://1.bp.blogspot.com/-ho2HWbx3HEU/UQZMo80HgpI/AAAAAAAAAFo/x-ra7hYOBNc/s400/Screen+Shot+2013-01-28+at+10.01.23.png" width="400" /></a></div>
<b><br /></b>
<b>Elvitegravir:</b><br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,2,0,0,1,0,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="37" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,2,0,0,1,0,1" width="320" /></a></div>
<b><br /></b></div>
<div style="text-align: center;">
<div class="separator" style="clear: both;">
</div>
<div class="separator" style="clear: both;">
<b>Cobicistat:</b></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,0,0,2,0,0,1,0,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="37" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,0,0,2,0,0,1,0,1" width="320" /></a></div>
<div class="separator" style="clear: both;">
<b><br /></b></div>
<div class="separator" style="clear: both;">
</div>
<div class="separator" style="clear: both;">
<b><br /></b></div>
<div class="separator" style="clear: both;">
<b>ATC Code :</b>&nbsp;<a href="http://www.whocc.no/atc_ddd_index/?code=J05AR09">J05AR09</a></div>
</div>
<div style="text-align: center;">
<b>Wikipedia :&nbsp;</b><a href="http://en.wikipedia.org/wiki/Stribild">Elvitegravir/Cobicistat&nbsp;/Emtricitabine/Tenofovir</a><br />
<br /></div>
<div>
<div style="text-align: justify;">
On August 27, FDA approved the complete regimen for treatment of Human Immunodeficiency Virus -1 (<a href="http://en.wikipedia.org/wiki/HIV-1#HIV-1">HIV-1</a>) infection in adults who are antiretroviral treatment-naïve. STRIBILD®, combination of a&nbsp;<a href="http://en.wikipedia.org/wiki/Integrase">HIV-1&nbsp;integrase</a>&nbsp;strand transfer inhibitor&nbsp;(<a href="http://en.wikipedia.org/wiki/Discovery_and_development_of_integrase_inhibitors#IN_strand_transfer_inhibitors_.28INSTIs.29">INSTI</a>) -&nbsp;<i><b>Elvitegravir</b></i>, a pharmacokinetic enhancer -&nbsp;<i><b>Cobicistat</b></i>&nbsp;and two nucleos(t)ide analog HIV-1&nbsp;<a href="http://en.wikipedia.org/wiki/Reverse_transcriptase">Reverse Transcriptase</a>&nbsp;(RT) inhibitors (<a href="http://en.wikipedia.org/wiki/Nucleoside_analogue_reverse_transcriptase_inhibitor">NRTI's</a>) -&nbsp;<i><b>Emtricitabine/Tenofovir disoproxil</b></i>.</div>
<br />
<div>
<div style="text-align: justify;">
Acquired immunodeficiency syndrome (<a href="http://en.wikipedia.org/wiki/AIDS">AIDS</a>) is a disease of the human&nbsp;<a href="http://en.wikipedia.org/wiki/Immune_system">immune system</a>&nbsp;caused by&nbsp;<a href="http://en.wikipedia.org/wiki/HIV">HIV</a>&nbsp;infection, in which progressive failure of the immune system allows life-threatening&nbsp;<a href="http://en.wikipedia.org/wiki/Opportunistic_infection">opportunistic infections</a>&nbsp;and&nbsp;<a href="http://en.wikipedia.org/wiki/Cancer">cancers</a>&nbsp;to thrive. HIV infects and kills vital cells involved in immune system such as&nbsp;<a href="http://en.wikipedia.org/wiki/Helper_T_cell">T helper cells</a>&nbsp;(specifically&nbsp;<a href="http://en.wikipedia.org/wiki/CD4">CD4+</a>&nbsp;T cells,&nbsp;<a href="http://en.wikipedia.org/wiki/Macrophage">macrophages</a>&nbsp;and&nbsp;<a href="http://en.wikipedia.org/wiki/Dendritic_cell">dendritic cells</a>. When CD4+ T cell numbers decile below a critical level,&nbsp;<a href="http://en.wikipedia.org/wiki/Cell-mediated_immunity">cell-mediated immunity</a>&nbsp;is lost and the body becomes progressively more susceptible to opportunistic infections.</div>
</div>
<br />
<div style="text-align: justify;">
HIV/AIDS is a global&nbsp;<a href="http://en.wikipedia.org/wiki/Pandemic">pandemic</a>. As of 2012 approximately 34 million people have HIV worldwide. Of these approximately 16.8 million are women and 3.4 million are less than 15 years old. For more information on the disease epidemiology or any other information on HIV/AIDS, check&nbsp;<a href="http://en.wikipedia.org/wiki/Epidemiology_of_HIV/AIDS">Wikipedia</a>&nbsp;or&nbsp;<a href="http://www.unaids.org/en/">UNAIDS</a>.</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://upload.wikimedia.org/wikipedia/commons/d/d7/HIV_Epidem.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="183" src="http://upload.wikimedia.org/wikipedia/commons/d/d7/HIV_Epidem.png" width="400" /></a></div>
<br />
<div style="text-align: justify;">
The management of HIV/AIDS typically includes the use of antiretroviral drugs which are medications for the treatment of infection of HIV. Different antiretroviral drugs restrain the growth and reproduction of HIV, that are broadly classified by the phase of the retrovirus life-cycle that the drug inhibits.</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.bcm.edu/cms_web/78//images/eidbd/hiv-life-cycle.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="300" src="http://www.bcm.edu/cms_web/78//images/eidbd/hiv-life-cycle.jpg" width="400" /></a></div>
<div class="separator" style="clear: both;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
The life-cycle of HIV (all steps 1 to 6) can be as short as about 1.5 days and HIV lacks proofreading enzymes. These cause the virus to mutate very rapidly, resulting in high genetic variability. When antiretroviral drugs are used improperly, these multi-drug resistant (MDR) strains can become dominant genotypes. This lead to development of combination therapy - wherein several drugs (<a href="http://en.wikipedia.org/wiki/Antiretroviral_drug#Classes_of_drugs">different classes of&nbsp;antiretroviral drugs</a>), typically three or four, are taken in combination, the approach is known as highly active antiretroviral therapy (<a href="http://en.wikipedia.org/wiki/HAART">HAART</a>).&nbsp;</div>
<div class="separator" style="clear: both;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://i-base.info/guides/files/2009/06/pillboy-big.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://i-base.info/guides/files/2009/06/pillboy-big.png" /></a></div>
<div class="separator" style="clear: both;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
In recent years, many such complex regimens has been developed and termed as <i>fixed-dose combinations</i>. Some other examples of fixed-dose combination drugs approved by FDA for HIV treatment can be found <a href="http://en.wikipedia.org/wiki/Fixed_dose_combination_(antiretroviral)">here</a>. And one such combination drug is&nbsp;STRIBILD®; which is a fixed-dose combination of&nbsp;<i>Elvitegravir</i>,&nbsp;<i>Cobicistat</i>,&nbsp;<i>Emtricitabine</i>&nbsp;and&nbsp;<i>Tenofovir DF</i>.&nbsp;Elvitegravir, emtricitabine and tenofovir directly suppress viral reproduction. Cobicistat increases the effectiveness of the combination by inhibiting liver enzymes that metabolise the other components. In this regimen of drugs&nbsp;Elvitegravir and&nbsp;Cobicistat are the new molecular entities (NME), the rest two&nbsp;emtricitabine (<a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021500s019lbl.pdf"><i>prescribing info.</i></a>) and&nbsp;tenofovir (<a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021356s042,022577s002lbl.pdf"><i>prescribing info.</i></a>) are pre-approved, prescribed NRTI drugs.</div>
<div class="separator" style="clear: both;">
<br /></div>
<div class="separator" style="clear: both; text-align: justify;">
<b>Elvitegravir</b>&nbsp;(<i>Research Code</i>: GS1937,&nbsp;<i>ChEMBL</i>:&nbsp;<a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL204656">CHEMBL204656</a>,&nbsp;<i>PubChem</i>:&nbsp;<a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5277135">CID 5277135</a>,&nbsp;<i>ChemSpider</i>:&nbsp;<a href="http://www.chemspider.com/Chemical-Structure.4441060">4441060</a>&nbsp;)&nbsp;inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection. Elvitegravir does not inhibit human&nbsp;<i>Topoisomerases I</i>&nbsp;or&nbsp;<i>II</i>.</div>
<div class="separator" style="clear: both;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-ej5cY-ocfm4/UQKdgLEWBHI/AAAAAAAAAFI/jcidomLUTWs/s1600/elti.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="200" src="http://3.bp.blogspot.com/-ej5cY-ocfm4/UQKdgLEWBHI/AAAAAAAAAFI/jcidomLUTWs/s200/elti.png" width="181" /></a></div>
<div class="separator" style="clear: both;">
<b>IUPAC Name&nbsp;</b>:&nbsp;6-(3-Chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid</div>
<div class="separator" style="clear: both;">
<b>Canonical SMILES&nbsp;</b>:&nbsp;COc1cc2N(C=C(C(=O)O)C(=O)c2cc1Cc3cccc(Cl)c3F)[C@H](CO)C(C)C</div>
<div class="separator" style="clear: both;">
<b>Standard InChI</b>&nbsp;: 1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1</div>
<b>Standard InChI Key</b>&nbsp;: JUZYLCPPVHEVSV-LJQANCHMSA-N<br />
<br />
<div style="text-align: justify;">
<b>Cobicistat</b>&nbsp;(<i>PubChem</i>:&nbsp;<a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25151504">CID 25151504</a>,&nbsp;<i>ChemSpider</i>:&nbsp;<a href="http://www.chemspider.com/Chemical-Structure.25084912">25084912</a>) is a selective, mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily. Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as elvitegravir, where bioavailability is limited and half-life is shortened by CYP3A-dependent metabolism.</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-cpxZA1R6J3I/UQKiNJ0vp8I/AAAAAAAAAFY/ZdOq_gzoEaQ/s1600/cobcistat.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="166" src="http://4.bp.blogspot.com/-cpxZA1R6J3I/UQKiNJ0vp8I/AAAAAAAAAFY/ZdOq_gzoEaQ/s320/cobcistat.png" width="320" /></a></div>
<br />
<br />
<div class="separator" style="clear: both;">
<b>IUPAC Name&nbsp;</b>:&nbsp;1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate</div>
<div class="separator" style="clear: both;">
<b>Canonical SMILES&nbsp;</b>:&nbsp;CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc4cncs4)Cc5ccccc5)cs1</div>
<div class="separator" style="clear: both;">
<b>Standard InChI</b>&nbsp;:&nbsp;1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1</div>
<div>
<br /></div>
<div>
<div style="text-align: justify;">
The recommended dose of STRIBILD is one tablet&nbsp;administered orally once a day, which contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate. Peak plasma concentrations were observed 4 hrs post-dose for elvitegravir with Cmax of 1.7 ± 0.4, 3 hrs for cobicistat with Cmax of 1.1 ± 0.4. Almost 98-99% of&nbsp;elvitegravir bound to human plasma, whereas&nbsp;cobicistat was 97-98% bound. Median terminal plasma half-life of 12.9 for&nbsp;elvitegravir was found with 94.8% and 6.7% of the administered dose excreted in feces and urine respectively. Cobicistat exhibited 3.5 hrs of plasma half-life with 86.2% and 8.2% of the administered dose excreted in feces and urine.</div>
</div>
<div>
<br />
Full prescribing information can be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203100s000lbl.pdf">here</a>.<br />
<br />
The license holder is <a href="http://www.gilead.com/">GILEAD</a>, and the product website is <a href="http://www.stribild.com/">www.stribild.com</a>.</div>
<div>
</div>
</div>
</div>
